5 questions answered from cited research · Plain language
For EGFR-mutant lung cancer that has spread to the lining of the brain (leptomeningeal metastasis), studies point to osimertinib, sometimes combined with bevacizumab, and pemetrexed as treatments linked to longer survival.
Read the full answer →Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and intracranial responses, though resistance can develop.
Read the full answer →Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.
Read the full answer →Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.
Read the full answer →Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor; targeted therapies like osimertinib show high intracranial response rates.
Read the full answer →